quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·2d
PRRelease
Nurix Therapeutics Inc. logo

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

NRIX· Nurix Therapeutics Inc.
Health Care
Original source

Companies

  • NRIX
    Nurix Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 8UpdateMorgan Stanley$36.00
  • Nov 24UpdateTruist$30.00
  • Oct 21UpdateMizuho$24.00
  • Mar 17UpdateLeerink Partners$16.00
  • Dec 10UpdateBTIG Research$35.00
  • Dec 6UpdateBMO Capital Markets$35.00

Related

  • SEC16d
    SEC Form 10-Q filed by Nurix Therapeutics Inc.
  • SEC16d
    Nurix Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR16d
    Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
  • PR17d
    Nurix Therapeutics to Participate in Upcoming Investor Conference
  • INSIDER21d
    SEC Form 4 filed by Ring Christine
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
  • SEC28d
    SEC Form DEF 14A filed by Nurix Therapeutics Inc.
  • SEC28d
    SEC Form DEFA14A filed by Nurix Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022